“Shingles is caused by the reactivation of the Varicella Zoster Virus (VZV) in nerves and is characterized by severe pain that can drastically reduce the quality of life for those affected.” Said Dr. Thomas Rau, Wintermute’s Chief Executive Officer. “We are very excited to expand our program into a clinical trial with shingles patients that are suffering. We’re confident that topical Solexan is both safe and effective against herpes virus infections, and this trial is critical step in demonstrating that effect.”
Leading shingles physician and Clinical Advisor to Wintermute Biomedical, Professor Myron Levin, has stated that “Shingles is a major health burden in the U.S. (1.3 million cases a year) and is equally prevalent in every region of the world. There is a great need for an effective treatment that will safely reduce the consequences of shingles.”In response to the critical unmet need in shingles patients, Wintermute Biomedical remains committed to developing and advancing new technology and treatments that address the widespread impact of shingles by reducing pain and enhancing lesion healing.
